John Cunningham virus (JCV), the etiological agent of progressive multifocal leukoencephalopathy (PML), is the first human polyomavirus described. After asymptomatic primary infection which occurs in childhood, the virus spreads by the hematogenous route from the primary site of infection to secondary sites including kidneys, lymphoid tissues, peripheral blood leukocytes, and brain to establish latent infection. During immunosuppression the virus undergoes molecular rearrangements that allow it to replicate in glial tissues causing PML. PML occurs in people with underlying immunodeficiency or in individuals being treated with potent immunomodulatory therapies. Although the hypothesis that immune deficiency is a predisposing factor for PML, there are many unsolved issues including the pathogenic mechanisms related to the interaction of JCV infection/reactivation with the host. This is due to the difficulty of propagating the virus in human cell cultures and the absence of an animal model. This review updates current understanding in the context of JCV and human disease.
John Cunningham virus: an overview on biology and disease of the etiological agent of the progressive multifocal leukoencephalopathy / Pietropaolo, V; Prezioso, C; Bagnato, F; Antonelli, G. - In: NEW MICROBIOLOGICA. - ISSN 1121-7138. - ELETTRONICO. - 41:3(2018), pp. 179-186.
John Cunningham virus: an overview on biology and disease of the etiological agent of the progressive multifocal leukoencephalopathy.
Pietropaolo V
Writing – Review & Editing
;Prezioso CWriting – Original Draft Preparation
;BAGNATO, FRANCESCA ROSARIAWriting – Review & Editing
;Antonelli GWriting – Review & Editing
2018
Abstract
John Cunningham virus (JCV), the etiological agent of progressive multifocal leukoencephalopathy (PML), is the first human polyomavirus described. After asymptomatic primary infection which occurs in childhood, the virus spreads by the hematogenous route from the primary site of infection to secondary sites including kidneys, lymphoid tissues, peripheral blood leukocytes, and brain to establish latent infection. During immunosuppression the virus undergoes molecular rearrangements that allow it to replicate in glial tissues causing PML. PML occurs in people with underlying immunodeficiency or in individuals being treated with potent immunomodulatory therapies. Although the hypothesis that immune deficiency is a predisposing factor for PML, there are many unsolved issues including the pathogenic mechanisms related to the interaction of JCV infection/reactivation with the host. This is due to the difficulty of propagating the virus in human cell cultures and the absence of an animal model. This review updates current understanding in the context of JCV and human disease.File | Dimensione | Formato | |
---|---|---|---|
Pietropaolo_John Cunningham virus_2018.pdf
solo gestori archivio
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
966.83 kB
Formato
Adobe PDF
|
966.83 kB | Adobe PDF | Contatta l'autore |
Pietropaolo_John Cunningham_2018.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
723.65 kB
Formato
Adobe PDF
|
723.65 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.